Jan 8 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES ANNOUNCES PUBLICATION OF POSITIVE
RESULTS
ON NEEDLE-BASED ENDOMICROSCOPY FOR THE CLINICAL MANAGEMENT OF
PANCREATIC CYSTIC LESIONS
* CLINICAL TRIAL PUBLISHED IN PEER-REVIEWED JOURNAL
DEMONSTRATES
DIAGNOSTIC YIELD FROM CELLVIZIO® SIGNIFICANTLY EXCEEDS STANDARD
OF CARE
* USE OF CELLVIZIO DRIVES OVERALL CHANGE IN CLINICAL
MANAGEMENT -
INCLUDING NEED FOR CONTINUED SURVEILLANCE OR SURGERY - IN 42.3%
OF CASES
* RESULTS OF THIS STUDY CLEARLY DEMONSTRATE THAT MFB AND
NCLE LEAD
TO SIGNIFICANT IMPROVEMENTS IN SPECIFIC PCL DIAGNOSIS, WHICH IN
TURN HAS MAJOR IMPACT IN CLINICAL MANAGEMENT
* THIS STUDY FURTHER ENHANCES GROWING BODY OF EVIDENCE
* SAYS BELIEVE EVIDENCE OF CHANGING PATIENT MANAGEMENT FOR
PANCREATIC CYSTS WILL HELP DRIVE ADOPTION IN U.S. GOING FORWARD
Source text for Eikon: ID:nBw807Fcxa
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))